icryo semaglutide Daniel Island Weight loss drug semaglutide reduces
Description
doi:10.1210/jendso/bvad016 PMID: 36789109
24.2% at 48 weeks in Phase 2 Tirzepatide : Up to 20.9% body weight reduction (SURMOUNT trials) Advantage : Retatrutide Regulatory Status# Retatrutide : Phase 1-3 clinical trials
The study found continued dose-dependent weight loss at these higher doses but also increased adverse event rates
Initial concerns that participants could lose weight when taking the drug turned out to be unfounded
